Is Orchid Pharma Turnaround Candidate?
Shaikhoology's Stock Analysis
#OrchidPhar - 474
Overview:-
Business got into trouble and filed insolvency which was taken over by Dhanuka Laboratories in 2020
MOAT- Company have few patented products (API)
Topline:-
YOY & QOQ improvement seen in recent results.
Profit Growth is Organic and Margin Expansion clearly visible
BottomLine :-
Debt reduction, Good Reserves and Positive Cash Flow shows Financial stability.
Valuations:-
Overvalued as of Now.
If Earning Growth Continues then valuations can be cheaper, needs EPS of 10-15 then stock price will attract new investors.
Technically - Chart is bullish at Cmp and their is hurdles also as trading in WDZ
Stock May See 1000-1200 levels(WSZ) if trades and sustains above 550 levels.
SHARED FOR EDUCATIONAL PURPOSE ONLY, I AM NOT SEBI REGISTERED ANALYST.
#OrchidPhar - 474
Overview:-
Business got into trouble and filed insolvency which was taken over by Dhanuka Laboratories in 2020
MOAT- Company have few patented products (API)
Topline:-
YOY & QOQ improvement seen in recent results.
Profit Growth is Organic and Margin Expansion clearly visible
BottomLine :-
Debt reduction, Good Reserves and Positive Cash Flow shows Financial stability.
Valuations:-
Overvalued as of Now.
If Earning Growth Continues then valuations can be cheaper, needs EPS of 10-15 then stock price will attract new investors.
Technically - Chart is bullish at Cmp and their is hurdles also as trading in WDZ
Stock May See 1000-1200 levels(WSZ) if trades and sustains above 550 levels.
SHARED FOR EDUCATIONAL PURPOSE ONLY, I AM NOT SEBI REGISTERED ANALYST.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.